Estimation of the Time of Pulmonary Metastasis in Colorectal Cancer Patients with Isolated Synchronous Liver Metastasis
|
|
- Natalie Neal
- 5 years ago
- Views:
Transcription
1 Jpn J Clin Oncol 2005;35(1)18 22 doi: /jjco/hyi010 Estimation of the Time of Pulmonary Metastasis in Colorectal Cancer Patients with Isolated Synchronous Liver Metastasis Sotaro Sadahiro 1, Toshiyuki Suzuki 1, Kenji Ishikawa 1, Tomoki Nakamura 1, Yoichi Tanaka 1, Kazuhiro Ishizu 1, Seiei Yasuda 1, Hiroyasu Makuuchi 1 and Chieko Murayama 2 1 Department of Surgery and 2 Radiology, Tokai University, School of Medicine, Isehara, Kanagawa, Japan Received September 5, 2004; accepted November 20, 2004 Objective: The aim of this study was to estimate the time when pulmonary metastases began to grow in colorectal cancer (CRC) patients with isolated synchronous liver metastasis based on the tumor doubling time (DT). Methods: We examined 23 pulmonary metastases in 14 patients detected after resection of liver metastases from CRC (group 1) and 19 pulmonary metastases in eight patients detected after initiation of hepatic arterial infusion chemotherapy for synchronous unresectable liver metastases (group 2). The regression line was determined from the chest X-ray films, and the DT was calculated. Results: We estimated the DTs of pulmonary metastases as and days in groups 1 and 2, respectively, and the time when pulmonary metastases began to grow as and days before the resection of liver metastases for 19 lesions in 12 out of 14 patients of group 1 and before resection of primary CRC in group 2, respectively. Conclusion: It appears that in some CRC patients in whom the metastatic site is considered to be limited to the liver at diagnosis, occult pulmonary metastasis has already taken place. Key words: colorectal cancer liver metastasis pulmonary metastasis tumor doubling time INTRODUCTION In patients with colorectal cancer (CRC), the most frequent metastatic site is the liver (1,2). When the liver is the only metastatic site, liver resection is performed in resectable cases, and hepatic arterial infusion (HAI) chemotherapy or systemic chemotherapy is performed in unresectable cases. Among them, liver resection and HAI chemotherapy are both local therapies. In patients with resectable hepatic metastases from CRC, recurrences are found in two-thirds of those who undergo liver resection, with the 5-year disease-free survival variously reported to be 15% (3), 28% (4) or 34% (5) after curative resection of liver metastases, which is not satisfactory at all. The percentage of patients whose recurrence site after liver resection is limited to the liver is variously reported as 41% (6), 47% (7) or 48% (8), with a high frequency of metastasis to other organs (9), the lung being the highest (10,11). In patients with unresectable hepatic metastases, development of extrahepatic metastases during the HAI chemotherapy period is often experienced (12 14). For reprints and all correspondence: Sotaro Sadahiro, Department of Surgery, Tokai University, Bohseidai Isehara, Kanagawa , Japan. sadahiro@is.icc.u-tokai.ac.jp Recently, significantly favorable disease-free survival was reported in patients who received combined HAI chemotherapy and systemic chemotherapy after liver resection for resectable hepatic metastases (15). On the other hand, in patients with unresectable hepatic metastases, favorable outcomes have been reported in those who underwent liver resection after the hepatic metastases became resectable because of systemic chemotherapy or HAI chemotherapy (16 18). A meta-analysis comparing HAI chemotherapy and systemic chemotherapy for unresectable hepatic metastases showed that the former yielded a significantly favorable response rate as compared with the latter, but no survival benefit (19). These findings strongly suggest that sufficient survival benefit cannot be obtained by liver resection or HAI chemotherapy alone, because both are local therapies and cannot prevent new development of extrahepatic metastases. Accordingly, we should consider suppressing possible extrahepatic metastases as well in order to improve the therapeutic outcome of hepatic metastases from CRC. To investigate the treatment strategy for synchronous liver metastasis from colorectal cancer, we need to estimate the time when extrahepatic metastases took place in patients whose extrahepatic metastases were discovered after hepatic metastases had been treated. Therefore, we examined in this study the patients with CRC having isolated synchronous liver metastases whose pulmonary metastases were detected after # 2005 Foundation for Promotion of Cancer Research
2 Jpn J Clin Oncol 2005;35(1) 19 liver resection and also whose pulmonary metastases were detected while undergoing HAI chemotherapy for unresectable liver metastases. PATIENTS AND METHODS Between 1981 and 1999, there were 117 CRC patients with isolated synchronous liver metastasis in our hospital. In 49 patients, liver resection was performed in addition to colorectal resection at the initial surgery. In 68 patients whose liver metastases were diagnosed as unresectable, resection of the primary CRC alone was performed. Fifty-one out of 68 patients received HAI chemotherapy with 5-fluorouracil (5-FU) post-operatively. 5-FU was infused continuously for 7 days biweekly and repeated in most cases (20,21). We investigated 23 pulmonary metastatic lesions in 14 patients who had undergone liver resection (group 1) and 19 pulmonary metastatic lesions in eight patients who had received HAI chemotherapy (group 2), the patients in both groups having assessable pulmonary metastases, followed by three or more chest X-ray examinations. In eight out of 14 patients who had undergone liver resection (group 1), HAI chemotherapy with 5-FU was performed postoperatively as adjuvant chemotherapy. Oral fluoropyrimidine alone was administered to the other two patients for >3 months. The other two patients received both HAI and oral fluoropyrimidines. The remaining two patients received no adjuvant chemotherapy. Eight patients who were diagnosed as having unresectable metastasis (group 2) received 5-FU HAI chemotherapy without systemic chemotherapy. We retrospectively measured the size of pulmonary metastases in two directions on the chest X-ray films. Tumor doubling time (DT) was calculated from the following equations (22). Using the equation DT = 0.1(t t 0 )/log dt log d 0, the regression line log d = at + b was obtained, and DT = log 2/3 a was calculated. At the time of resection of the primary colorectal cancer, t equals 0 (t = 0), and thus the size of the pulmonary metastatic lesion at the time of resection of primary colorectal cancer was calculated from log d = b. RESULTS Table 1 shows the DT of 23 pulmonary metastases in 14 patients who underwent liver resection (group 1), the estimated time when pulmonary metastasis began to grow, and the estimated size of pulmonary metastases at the time of resection of the primary CRC and liver metastasis. The DT of pulmonary metastases was days. The time when pulmonary metastases began to grow for 19 lesions in 12 out of 14 patients was estimated to be days (median, 373 days) before the resection of primary CRC and liver metastases. The size of these pulmonary metastases at the time of resection of the primary CRC and liver metastases was estimated to be mm (median, 3.1 mm). The time when pulmonary metastases began to grow for four lesions in three out of 14 patients was estimated to be days after the resection of the primary CRC and liver metastases. In all of these three cases where the pulmonary metastases were considered to have occurred after the resection of primary CRC and liver metastases, other metastases had already been detected in the remnant liver or at local sites before the detection of pulmonary metastasis. Table 2 shows the DT of 19 pulmonary metastases in eight patients who received HAI chemotherapy after resection of the primary CRC alone because the liver metastasis was diagnosed as unresectable (group 2), the estimated time when pulmonary metastases began to grow, and the estimated size of pulmonary metastases at the time of resection of the primary CRC. The DT of pulmonary metastases was days, with no significant difference from that of group 1. In one out of eight patients, peritoneal metastasis was detected synchronously with pulmonary metastases. The time when pulmonary metastases began to grow in 19 lesions was estimated to be before the resection of primary CRC, being days (median, 502 days) before the resection. The size of pulmonary metastases at the time of resection of the primary CRC was estimated to be mm (median, 4.2 mm). No difference was observed in the DT between the seven lesions in four patients who received systemic chemotherapy with oral fluoropyrimidine after liver resection, and the 16 lesions in 10 patients without (Table 3). There was also no difference in the DT between the 37 lesions in 18 patients who received 5-FU HAI chemotherapy after liver resection or for unresectable liver metastases and the five lesions in four patients without. DISCUSSION HAI chemotherapy for liver metastasis from CRC has yielded a significantly favorable response rate compared with systemic chemotherapy, but no survival benefit (19). It may be mainly because both liver resection and HAI chemotherapy are local therapies and thus cannot prevent new development of extrahepatic metastases. Safi et al. reported that the combined use of HAI chemotherapy and systemic chemotherapy for liver metastasis from CRC reduced the frequency of extrahepatic spread of cancer as compared with HAI chemotherapy alone (23). Significantly favorable disease-free survival was also reported recently with the combined use of HAI chemotherapy and systemic chemotherapy after liver resection (15). These results indicate that we need to suppress extrahepatic metastases along with treating liver metastases to improve further the therapeutic outcome in patients with isolated liver metastasis from CRC. In order to do so, it is crucial that we know the time when extrahepatic metastasis begins to grow. Based on the chest X-ray films, Collins (24) reported the mean DT of pulmonary metastases in CRC to be 116 days (range, days) in 25 lesions, whereas Spratt and Spratt (25) reported it to be 109 days in 10 lesions. The overall DT of 42 lesions that we examined in this study was days, being shorter compared with those previously reported. Basing our calculations on this DT, we estimated the time
3 20 Time of development of CRC metastasis Table 1. Lung metastasis (MET) from colorectal cancer in patients who underwent liver resection (group 1) Case MET site following liver resection prior to lung MET Lesion Interval between initial surgery and clinical lung MET (days) Tumor doubling time (days) Development of lung MET prior to initial surgery (days) 1 Liver, local Local Liver None Local None Local None Liver None Lymph node Local Liver Liver Size of lung MET at initial surgery (mm) when pulmonary metastases began to grow in 14 patients in whom pulmonary metastases were newly detected during the follow-up period after resection of primary site and liver metastasis (group 1) to be days (median, 373 days) before the resection in 19 lesions in 12 patients, with the size of pulmonary metastases estimated as having already reached mm (median, 3.1 mm) at the time of resection of the primary CRC and liver metastases. In four lesions in three patients, the development time of pulmonary metastases was estimated to be days after the resection. In all these three cases, new metastases had been detected in the remnant liver or at local sites before pulmonary metastasis was diagnosed, indicating that the pulmonary metastasis may be a secondary metastasis from the remnant liver or local sites. In addition, in patients in whom pulmonary metastases were detected during or after receiving HAI chemotherapy for liver metastases (group 2), the time when pulmonary metastases began to grow was estimated to be days (median, 502 days) before the resection of the primary site of the CRC and initiation of HAI chemotherapy. The size of pulmonary metastases was estimated to have already reached mm (median, 4.2 mm) by the time of surgery for the primary lesion, thus indicating that the pulmonary metastases did not develop during HAI chemotherapy. Adjuvant chemotherapy has been reported to prolong disease-free survival (26 28). We have reported that, in cases where recurrence occurred after curative resection, the intervals between surgery and recurrence with or without adjuvant chemotherapy were and months, respectively, in colon cancer, and and months, respectively, in rectal cancer, indicating that adjuvant chemotherapy significantly prolonged the interval until recurrence (29). In this study, however, although the DT of pulmonary metastases with systemic chemotherapy or HAI chemotherapy after liver resection tended to be longer compared with that of patients without chemotherapies, the difference was not significant and the effect of chemotherapy on the tumor DT was not clear. Using the reverse transcription polymerase chain reaction (RT PCR) technique, detection of a minute amount of cancer cells in the blood has become possible. Hayashi et al. (30) and Miyazono et al. (31) reported that an increase in detection rate of cancer cells in the blood due to intraoperative manipulation could accelerate metastasis. However, we have reported that using semi-nested RT PCR with CEA mrna as a target, we
4 Jpn J Clin Oncol 2005;35(1) 21 Table 2. Lung metastasis (MET) from colorectal cancer in patients who underwent hepatic arterial infusion chemotherapy (group 2) Case MET site following liver resection prior to lung MET Lesion Interval between initial surgery and clinical lung MET (days) Tumor doubling time (days) Development of lung MET prior to initial surgery (days) 15 None None None Peritoneum None None None None Size of lung MET at initial surgery (mm) Table 3. Relationship between the tumor doubling time and chemotherapy No. of lesions Doubling time (days) P-value Hepaticarterial infusion chemotherapy Yes No Systemic chemotherapy Yes No detected cancer cells in the portal vein and peripheral blood immediately after celiotomy and before examining the tumorbearing bowel, and that there was no significant difference in the expression level of CEA mrna between the blood from the portal vein and from peripheral blood, with a detection rate reaching as high as 38% even in early cancer of stage I (32). From these results, it was assumed that in many patients with CRC, cancer cells are shed into the bloodstream before a clinical diagnosis of cancer is made. Our results show that most of the pulmonary metastases which developed during the follow-up period in patients with synchronous liver metastases were already present at the time when CRC was diagnosed, at a size of 34 mm. In conclusion, it appears that some CRC patients already have pulmonary metastases even when the metastatic sites are considered to be limited to the liver. Therefore, we should consider suppressing possible extrahepatic metastases as well to improve the therapeutic outcome of synchronous hepatic metastases from CRC. However, we cannot at present differentiate these patients with occult metastasis from others. References 1. Galandiuk S, Wieand HS, Moertel CG, Cha SS, Fitzgibbons RJ Jr, Pemberton JH et al. Patterns of recurrence after curative resection of carcinoma of the colon and rectum. Surg Gynecol Obstet 1992;174: Tominaga T, Sakabe T, Koyama Y, Hamano K, Yasutomi M, Takahashi T et al. Prognostic factors for patients with colon or rectal carcinoma treated with resection only. Five-year follow-up report. Cancer 1996;78: Nordlinger B, Guiguet M, Vaillant J, Balladur P, Boudjema K, Bachellier P et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer 1996;77: Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 2002;235: Scheele J, Stangl R, Altendorf-Hofmann A, Gall FP. Indicators of prognosis after hepatic resection for colorectal secondaries. Surgery 1991;110: Gennari L, Doci R, Bignami P, Bozzetti F. Surgical treatment of hepatic metastases from colorectal cancer. Ann Surg 1986;2003: Hohenberger P, Schlag P, Schwarz V, Herfarth C. Tumor recurrence and options for further treatment after resection of liver metastases in patients with colorectal cancer. J Surg Oncol 1990;44: Fong Y, Cohen AM, Fortner JG, Enker WE, Turnbull AD, Coit DG et al. Liver resection for colorectal metastases. J Clin Oncol 1997;15: Cady B, Jenkins RL, Steele GD Jr, Lewis WD, Stone MD, McDermott WV et al. Surgical margin in hepatic resection for colorectal metastasis: a
5 22 Time of development of CRC metastasis critical and improvable determinant of outcome. Ann Surg 1998;227: Steele G Jr. Natural history studies and the evolution of regional treatment modalities for patientswith isolated liver metastases fromprimarycolon and rectum carcinoma. Cancer Control 1996;3: Fortner JG. Recurrence of colorectal cancer after hepatic resection. Am J Surg 1988;155: MetzgerU, Weder W, Rothlin M, LargiaderF. PhaseII studyof intra-arterial fluorouracil and mitomycin-c for liver metastases of colorectal cancer. Recent results. Cancer Res 1991;121: Howell JD, McArdle CS, Kerr DJ, Buckles J, Ledermann JA, Taylor I et al. A phase II study of regional 2-weekly 5-fluorouracil infusion with intravenous folinic acid in the treatment of colorectal liver metastases. Br J Cancer 1997;76: Link KH, Pillasch J, Formentini A, Sunelaitis E, Leder G, Safi F et al. Downstaging by regional chemotherapy of non-resectable isolated colorectal liver metastases. Eur J Surg Oncol 1999;25: Kemeny MM, Adak S, Gray B, Macdonald JS, Smith T, Lipsitz S et al. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy an intergroup study. J Clin Oncol 2002;20: Bismuth H, Adam R, Levi F, Farabos C, Waechter F, Castaing D et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996;224: Clavien P, Selzner N, Morse M, Selzner M, Paulson E. Downstaging of hepatocellular carcinoma and liver metastases from colorectal cancer by selective intra-arterial chemotherapy. Surgery 2002;131: Miyanari N, Mori T, Takahashi K, Yasuno M. Evaluation of aggressively treated patients with unresectable multiple liver metastases from colorectal cancer. Dis Colon Rectum 2002;45: Meta-Analysis Group in Cancer. Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst 1996;88: Sadahiro S, Suzuki T, Tokunaga N, Tajima T, Makuuchi H, Ohtaki M. Prevention of hepatic artery occlusion during continuous infusion of fluorouracil using liposteroid. Am J Roentgenol 2000:175: Sadahiro S, Suzuki T, Ishikawa K, Yasuda S, Tajima T, Makuuchi H et al. Prophylactic hepatic arterial infusion chemotherapy for the prevention of liver metastasis in patients with colon carcinoma. A randomized controlled trial. Cancer 2004:100: Philippe E, Gal YL. Growth of seventy-eight recurrent mammary cancers, quantitative study. Cancer 1968;21: Safi F, Bittner R, Roscher R, Schuhmacher K, Gaus W, Beger GH. Regional chemotherapy for hepatic metastases of colorectal carcinoma (continuous intraarterial versus continuous intraarterial/intravenous therapy). Results of a controlled clinical trial. Cancer 1989;64: Collins VP. Time of occurrence of pulmonary metastasis from carcinoma of colon and rectum. Cancer 1962;15: Spratt JS, Spratt TL. Rates of growth of pulmonary metastases and host survival. Ann Surg 1964;159: Fisher B, Wolmark N, Rockette H, Redmond C, Deutsch M, Wickerham DL et al. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. J Natl Cancer Inst 1988;80: Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990;322: Wolmark N, Rockette H, Fisher B, Wickerham DL, Redmond C, Fisher ER et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 1993;11: Sadahiro S, Suzuki T, Ishikawa K, Nakamura T, Tanaka Y, Masuda T et al. Recurrence patterns after curative resection of colorectal cancer in patients followed for a minimum of ten years. Hepatogastroenterology 2003;53: Hayashi N, Egami H, Kai M, Kurusu Y, Takano S, Ogawa M. No-touch isolation technique reduces intraoperative shedding of tumor cells into the portal vein during resection of colorectal cancer. Surgery 1999;125: Miyazono F, Takao S, Natsugoe S, Uchikura K, Kijima F, Aridome K et al. Molecular detection of circulating cancer cells during surgery in patients with biliary pancreatic cancer. Am J Surg 1999;177: Sadahiro S, Suzuki T, Tokunaga N, Yurimoto S, Yasuda S, Tajima T et al. Detection of tumor cells in the portal and peripheral blood of patients with colorectal carcinoma using competitive reverse transcriptase polymerase chain reaction. Cancer 2001;92:
ORIGINAL ARTICLE. A Second Liver Resection Due to Recurrent Colorectal Liver Metastases. accepted as the only curative
ORIGINAL ARTICLE A Second Liver Resection Due to Recurrent Colorectal Liver Metastases Antonio Sa Cunha, MD; Christophe Laurent, MD; Alexandre Rault, MD; Philippe Couderc, MD; Eric Rullier, MD; Jean Saric,
More informationRisk factors for cancer recurrence or death within 6 months after liver resection in patients with colorectal cancer liver metastasis
ORIGINAL ARTICLE pissn 2288-6575 eissn 2288-6796 http://dx.doi.org/10.4174/astr.2016.90.5.257 Annals of Surgical Treatment and Research Risk factors for cancer recurrence or death within 6 months after
More informationSurgical Management of Advanced Stage Colon Cancer. Nathan Huber, MD 6/11/14
Surgical Management of Advanced Stage Colon Cancer Nathan Huber, MD 6/11/14 Colon Cancer Overview Approximately 50,000 attributable deaths per year Colorectal cancer is the 3 rd most common cause of cancer-related
More informationCurrent Status of Adjuvant Therapy for Colorectal Cancer
Review Article [1] May 01, 2004 By Michael J. O connell, MD [2] Adjuvant therapy with chemotherapy and/or radiation therapy in addition to surgery improves outcome for patients with high-risk carcinomas
More informationComparative Efficacy of Adjuvant Chemotherapy in Patients With Dukes B Versus Dukes C Colon Cancer: Results From
Comparative Efficacy of Adjuvant Chemotherapy in Patients With Dukes B Versus Dukes C Colon Cancer: Results From Four National Surgical Adjuvant Breast and Bowel Project Adjuvant Studies (C-01, C-02, C-03,
More informationQuality of Survival Reporting in Chemotherapy and Surgery Trials in Patients with Metastatic Colorectal Carcinoma
1389 Quality of Survival Reporting in Chemotherapy and Surgery Trials in Patients with Metastatic Colorectal Carcinoma Robert C. G. Martin, M.D. 1,2 Vedra A. Augenstein, M.D. 1,2 Charles R. Scoggins, M.D.
More informationTumor Marker Evolution: Comparison with Imaging for Assessment of Response to Chemotherapy in Patients with Colorectal Liver Metastases
Ann Surg Oncol DOI 1.1245/s1434-9-887-5 ORIGINAL ARTICLE HEPATOBILIARY TUMORS Tumor Marker Evolution: Comparison with Imaging for Assessment of Response to Chemotherapy in with Colorectal Liver Metastases
More informationCorrespondence should be addressed to Roland Andersson,
Gastroenterology Research and Practice Volume 2012, Article ID 568214, 4 pages doi:10.1155/2012/568214 Research Article Repeated Liver Resection for Colorectal Liver Metastases: A Comparison with Primary
More informationColorectal Liver Metastases Metachronous
Colorectal Liver Metastases Metachronous Professor Rowan Parks Professor of Surgical Sciences University of Edinburgh No disclosures Natural History of Unresected Untreated Colorectal Metastases Year N
More informationHepatic Arterial Infusion of Chemotherapy for Hepatic Metastases From Colorectal Cancer
Hepatic arterial infusion of chemotherapy still plays a role in selected patients with colorectal cancer and hepatic metastases. Annie Toja. Antibes, France, Leisure Boats. Acrylic. Hepatic Arterial Infusion
More informationCOLON CANCER FOLLOW UP GUIDELINES
COLON CANCER FOLLOW UP GUIDELINES CAGPO Dr. Raziya Mia October 1, 2016 1 DISCLOSURES NONE 2 MITIGATING POTENTIAL BIAS Recommendations are consistent with published guidelines American Society of Clinical
More informationHepatic arterial infusion pump chemotherapy for colorectal liver metastases: an old technology in a new era
Curr Oncol, Vol. 21, pp. e116-121; doi: http://dx.doi.org/10.3747/co.21.1592 HAI PUMP CHEMOTHERAPY FOR CRC METASTASIS REVIEW ARTICLE Hepatic arterial infusion pump chemotherapy for colorectal liver metastases:
More informationManagement of colorectal cancer liver metastases
Management of colorectal cancer liver metastases Aliakbarian M. M.D. Assistant professor of surgery Organ Transplant & Hepatopancreatobiliary Surgeon SUBJECTS The importance of surgical resection in colorectal
More informationRepeated Liver Resection for Colorectal Liver Metastases: A Comparison with Primary Liver Resections concerning Perioperative and Long-Term Outcome.
Repeated Liver Resection for Colorectal Liver Metastases: A Comparison with Primary Liver Resections concerning Perioperative and Long-Term Outcome. Jönsson, Kristoffer; Gröndahl, Gerd; Salö, Martin; Tingstedt,
More informationPeritoneal Involvement in Stage II Colon Cancer
Anatomic Pathology / PERITONEAL INVOLVEMENT IN STAGE II COLON CANCER Peritoneal Involvement in Stage II Colon Cancer A.M. Lennon, MB, MRCPI, H.E. Mulcahy, MD, MRCPI, J.M.P. Hyland, MCh, FRCS, FRCSI, C.
More informationHepatic resection for colorectal liver metastases: prospective study
Key words: Colorectal neoplasms; Hepatectomy; Survival analysis CL Liu ST Fan CM Lo WL Law IOL Ng J Wong Hong Kong Med J 2002;8:329-33 The University of Hong Kong, Queen Mary Hospital, 102 Pokfulam Road,
More informationCurrent Treatment of Colorectal Metastases. Dr. Thavanathan Surgical Grand Rounds February 1, 2005
Current Treatment of Colorectal Metastases Dr. Thavanathan Surgical Grand Rounds February 1, 2005 25% will have metastases at initial presentation 25-50% 50% will develop metastases later 40% of potentially
More informationMANAGEMENT OF COLORECTAL METASTASES. Robert Warren, MD. The Postgraduate Course in General Surgery March 22, /22/2011
MANAGEMENT OF COLORECTAL METASTASES Robert Warren, MD The Postgraduate Course in General Surgery March 22, 2011 Local Systemic LIVER TUMORS:THERAPEUTIC OPTIONS Hepatoma Cholangio. Neuroendo. Colorectal
More informationStage III Colon Cancer Susquehanna Cancer Center Warren L Robinson, MD, FACP May 9, 2007
Stage III Colon Cancer Susquehanna Cancer Center 1997-21 Warren L Robinson, MD, FACP May 9, 27 Stage III Colon Cancer Susquehanna Cancer Center 1997-21 Colorectal cancer is the third most common cancer
More informationAdjuvant Chemotherapy for Patients with Resected Dukes C and High-risk B2 Colon Cancer with Fluorouracil and Levamisole
733 Adjuvant Chemotherapy for Patients with Resected Dukes C and High-risk B2 Colon Cancer with Fluorouracil and Levamisole E Au,*FAMS, M Med (Int Med), MRCP, P T Ang,**FAMS, FACP, FRCP (Edin), F Seow-Choen,***FAMS,
More informationEfficacy and Toxicity of Adjuvant Chemotherapy in Elderly Patients with Colon Carcinoma
1931 Efficacy and Toxicity of Adjuvant Chemotherapy in Elderly Patients with Colon Carcinoma A 10-Year Experience of the Geisinger Medical Center Farid Fata, M.D. 1 Ayoub Mirza, M.D. 2 G. Craig Wood, M.S.
More informationFactors associated with delayed time to adjuvant chemotherapy in stage iii colon cancer
Curr Oncol, Vol. 21, pp. 181-186 doi: http://dx.doi.org/10.3747/co.21.1963 DELAYED TIME TO ADJUVANT CHEMOTHERAPY ORIGINAL ARTICLE Factors associated with delayed time to adjuvant chemotherapy in stage
More informationAdjuvant therapies for large bowel cancer Wasantha Rathnayake, MD
LEADING ARTICLE Adjuvant therapies for large bowel cancer Wasantha Rathnayake, MD Consultant Clinical Oncologist, National Cancer Institute, Maharagama, Sri Lanka. Key words: Large bowel; Cancer; Adjuvant
More informationPAPER. Interval Hepatic Resection of Colorectal Metastases Improves Patient Selection
PAPE Interval Hepatic esection of Colorectal Metastases Improves Patient Selection aura A. ambert, MD; Thomas A. Colacchio, MD; ichard J. Barth, Jr, MD Hypothesis: Interval reevaluation for resectability
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GASTROINTESTINAL RECTAL CANCER GI Site Group Rectal Cancer Authors: Dr. Jennifer Knox, Dr. Mairead McNamara 1. INTRODUCTION 3 2. SCREENING AND
More informationColon Cancer Liver Metastases: Liver-Directed Therapy
Colon Cancer Liver Metastases: Liver-Directed Therapy Shishir K. Maithel, MD FACS Assistant Professor of Surgery Division of Surgical Oncology Winship Cancer Institute Emory University August 10, 2014
More informationHEPATIC ARTERIAL INFUSION OF CHEMOTHERAPY AFTER RESECTION OF HEPATIC METASTASES
HEPATIC ARTERIAL INFUSION OF CHEMOTHERAPY AFTER RESECTION OF HEPATIC METASTASES HEPATIC ARTERIAL INFUSION OF CHEMOTHERAPY AFTER RESECTION OF HEPATIC METASTASES FROM COLORECTAL CANCER NANCY KEMENY, M.D.,
More informationAntimetastatic Intraoperative Chemotherapy of Human Colon Tumors in the Livers of Nude Mice
2464 Vol. 6, 2464 2468, June 2000 Clinical Cancer Research Antimetastatic Intraoperative Chemotherapy of Human Colon Tumors in the Livers of Nude Mice Babak Rashidi, Zili An, Fang-Xian Sun, A. R. Moossa,
More informationHow to deal with synchronous primary and liver metastases
How to deal with synchronous primary and liver metastases Luis Sabater Ortí MD, PhD Associate Professor University of Valencia European Board Surgical Qualification HBP (EBSQ-HPB) Department of Surgery.
More informationTreatment of Locally Advanced Rectal Cancer: Current Concepts
Treatment of Locally Advanced Rectal Cancer: Current Concepts James J. Stark, MD, FACP Medical Director, Cancer Program and Palliative Care Maryview Medical Center Professor of Medicine, EVMS Case Presentation
More informationManchester Cancer Colorectal Pathway Board: Guidelines for management of colorectal hepatic metastases
Manchester Cancer Colorectal Pathway Board: Guidelines for management of colorectal hepatic metastases Date: April 2015 Date for review: April 2018 1. Principles The recognised specialist HPB MDT for Greater
More informationImpact of Adjuvant Chemotherapy in Patients With Curatively Resected Stage IV Colorectal Cancer
Impact of in Patients With Curatively Resected Stage IV Colorectal Cancer Hirotoshi Kobayashi, MD, FACS, Kenjiro Kotake, MD, and Kenichi Sugihara, MD, Study Group for Peritoneal Metastasis from Colorectal
More informationSurvival Outcomes of Liver Metastasectomy in Colorectal Cancer Cases: A Single-Center Analysis in Turkey
DOI:http://dx.doi.org/10.7314/APJCP.2014.15.13.5195 Survival after Liver Metastasectomy in Colorectal Cancer Cases in Turkey RESEARCH ARTICLE Survival Outcomes of Liver Metastasectomy in Colorectal Cancer
More informationTrattamento chirurgico delle lesioni epatiche secondarie difficili. Adelmo Antonucci Chirurgia Oncologica e Epato-bilio-pancreatica
Trattamento chirurgico delle lesioni epatiche secondarie difficili Adelmo Antonucci Chirurgia Oncologica e Epato-bilio-pancreatica What does it mean difficult lesions? Diagnosis Treatment Small size Unfit
More informationSimultaneous Liver and Colorectal Resections Are Safe for Synchronous Colorectal Liver Metastasis
Simultaneous Liver and Colorectal Resections Are Safe for Synchronous Colorectal Liver Metastasis Robert Martin, MD, Philip Paty, MD, Yuman Fong, MD, FACS, Andrew Grace, MD, Alfred Cohen, MD, FACS, Ronald
More informationIntroduction. Case Report
Case Report A patient who showed a pathologically complete response after undergoing treatment with XELOX plus bevacizumab for synchronous liver metastasis of grade H2 from sigmoid colon cancer Yasuhito
More informationAggressive surgery in the multimodality treatment of liver metastases from colorectal cancer
Journal of BUON 12: 209-213, 2007 2007 Zerbinis Medical Publications. Printed in Greece ORIGINAL ARTICLE Aggressive surgery in the multimodality treatment of liver metastases from colorectal cancer N.
More informationBACKGROUND: STUDY DESIGN: RESULTS: CONCLUSIONS:
Improved Survival after Resection of Liver and Lung Colorectal Metastases Compared with Liver-Only Metastases: A Study of 112 Patients with Limited Lung Metastatic Disease Antoine Brouquet, MD, Jean Nicolas
More informationCase Conference. Craig Morgenthal Department of Surgery Long Island College Hospital
Case Conference Craig Morgenthal Department of Surgery Long Island College Hospital Neoadjuvant versus Adjuvant Radiation Therapy in Rectal Carcinoma Epidemiology American Cancer Society statistics for
More informationSECONDARIES: A PRELIMINARY REPORT
HPB Surgery, 1990, Vol. 2, pp. 69-72 Reprints available directly from the publisher Photocopying permitted by license only 1990 Harwood Academic Publishers GmbH Printed in the United Kingdom CASE REPORTS
More informationTreatment strategy of metastatic rectal cancer
35.Schweizerische Koloproktologie-Tagung Treatment strategy of metastatic rectal cancer Gilles Mentha University hospital of Geneva Bern, January 18th, 2014 Colorectal cancer is the third most frequent
More informationPredicting recurrence and metastasis of primary esophageal cancer with or without lymph node metastasis
ONCOLOGY REPORTS 15: 809-814, 2006 809 Predicting recurrence and metastasis of primary esophageal cancer with or without lymph node metastasis TAKAYUKI TAJIMA 1, MASAYA MUKAI 2, SHINKICHI SATO 3, HIROMI
More informationNomogram for prediction of prognosis in patients with initially unresectable colorectal liver metastases
Original article Nomogram for prediction of prognosis in patients with initially unresectable colorectal liver metastases K. Imai 1,2,5, M.-A. Allard 1,2,4, C. Castro Benitez 1,2,4,E.Vibert 1,3,4, A. Sa
More informationProposal of a new and simple staging system of colorectal liver metastasis
PO Box 2345, Beijing 123, China World J Gastroenterol 26 November 21; 12(43): 6961-6965 World Journal of Gastroenterology ISSN 17-9327 wjg@wjgnet.com 26 The WJG Press. All rights reserved. COLORECTAL CANCER
More informationAssessing the management of hepatic colorectal cancer metastases: is treatment consistent in Ontario?
DOI:10.1111/j.1477-2574.2012.00467.x HPB ORIGINAL ARTICLE Assessing the management of hepatic colorectal cancer metastases: is treatment consistent in Ontario? Lakhbir Sandhu 1, Adrian Fox 1, Cindy Nhan
More informationNicolae Bacalbasa Carol Davila University Of Medicine and Pharmacy
Nicolae Bacalbasa Carol Davila University Of Medicine and Pharmacy Approximately 5% to 10% of breast cancers are metastatic at diagnosis (1) 50% of breast cancer patients will develop distant metastases
More informationSelection of Patients for Resection of Hepatic Colorectal Metastases: Expert Consensus Statement
Annals of Surgical Oncology, 13(10): 1261 1268 DOI: 10.1245/s10434-006-9023-y Selection of Patients for Resection of Hepatic Colorectal Metastases: Expert Consensus Statement Chusilp Charnsangavej, MD,
More informationTreatment of Colorectal Liver Metastases State of the Art
Treatment of Colorectal Liver Metastases State of the Art Eddie K. Abdalla, MD, FACS Professor and Chairman of Surgery Chief of Hepatobiliary Surgery Hilton Metropolitan Palace Hotel Beirut 16 November,
More informationNorthwestern University, Division of Hematology/Oncology, Chicago, Illinois, USA. Key Words. Colon cancer Stage II Adjuvant chemotherapy
The Oncologist Dialogues in Oncology Adjuvant Therapy in Stage II Colon Cancer: Current Approaches LISA BADDI, AL BENSON III Northwestern University, Division of Hematology/Oncology, Chicago, Illinois,
More informationManagement of Liver Metastasis from Colorectal Carcinoma. Aisha White, M.D. SUNY Downstate Division of Transplantation
Management of Liver Metastasis from Colorectal Carcinoma Aisha White, M.D. SUNY Downstate Division of Transplantation Management of Colorectal Liver Metastasis Epidemiology 25% of patients diagnosed
More informationRadiation Therapy for Liver Malignancies
Outline Radiation Therapy for Liver Malignancies Albert J. Chang, M.D., Ph.D. Department of Radiation Oncology, UCSF March 23, 2014 Rationale for developing liver directed therapies Liver directed therapies
More informationSimultaneous Liver and Colorectal Resections Are Safe for Synchronous Colorectal Liver Metastases
J Gastrointest Surg (2010) 14:1974 1980 DOI 10.1007/s11605-010-1284-x ORIGINAL ARTICLE Simultaneous Liver and Colorectal Resections Are Safe for Synchronous Colorectal Liver Metastases Yanxin Luo & Lei
More informationEfficiency and tolerability of 5- fluorouracil-based adjuvant chemotherapy in elderly patients with colorectal carcinoma
Turkish Journal of Cancer Volume 34, No.4, 2004 139 Efficiency and tolerability of 5- fluorouracil-based adjuvant chemotherapy in elderly patients with colorectal carcinoma LHAN ÖZTOP 1, ARZU YAREN 1,
More informationEvaluation of the Efficacy of Modified De Gramont and Modified FOLFOX4 Regimens for Adjuvant Therapy of Locally Advanced Rectal Cancer
Efficacy of Modified De Gramont and FOLFOX4 Regimens for Locally Advanced Rectal Cancer RESEARCH COMMUNICATION Evaluation of the Efficacy of Modified De Gramont and Modified FOLFOX4 Regimens for Adjuvant
More informationClinical Significance of Serum CEA Protein and CEA mrna After Resection of Colorectal Liver Metastases
Clinical Significance of Serum CEA Protein and CEA mrna After Resection of Colorectal Liver Metastases M. KIJIMA, S. TOGO, Y. ICHIKAWA, M. MIURA, S. YAMAGISHI, K. MATSUO, K. TANAKA, H. MASUI, T. ISHIKAWA,
More informationManagement of Stage IV Colorectal Cancer: Expanding the Horizon
Management of Stage IV Colorectal Cancer: Expanding the Horizon May Tee, MD, MPH and Jan Franko, MD, PhD MercyOne Surgical Group (Mercy Surgical Affiliates) GI Oncology Conference 2019 March 1, 2019 Disclosures
More informationExtension of the Frontiers of Surgical Indications in the Treatment of Liver Metastases From Colorectal Cancer
ANNALS OF SURGERY Vol. 231, No. 4, 487 499 2000 Lippincott Williams & Wilkins, Inc. Extension of the Frontiers of Surgical Indications in the Treatment of Liver Metastases From Colorectal Cancer Long-Term
More informationIndeterminate Pulmonary Nodules in Patients with Colorectal Cancer
Indeterminate Pulmonary Nodules in Patients with Colorectal Cancer Jai Sule 1, Kah Wai Cheong 2, Stella Bee 2, Bettina Lieske 2,3 1 Dept of Cardiothoracic and Vascular Surgery, University Surgical Cluster,
More informationThe Surgical Management of Colorectal Metastases
11th July 2017 Bowel Cancer UK The Surgical Management of Colorectal Metastases Ben Cresswell MD(Res) FRCS Consultant HPB Surgeon The Basingstoke Hepatobiliary Unit United Kingdom Surgical Management of
More informationintent treatment be in the elderly?
Gastric cancer: How strong can curative intent treatment be in the elderly? Caio Max S. Rocha Lima, M.D. Professor of Medicine University of Miami & Sylvester Cancer Center Gastric cancer: epidemiology
More informationIt was predicted that in 1997, colon cancer would
Surgery for Recurrent Colon Cancer: Strategies for Identifying Resectable Recurrence and Success Rates after Resection Richard M. Goldberg, MD; Thomas R. Fleming, PhD; Catherine M. Tangen, DrPH; Charles
More informationSurgical. Gastroenterology. Evaluating the efficacy of tumor markers CA 19-9 and CEA to predict operability and survival in pancreatic malignancies
Tropical Gastroenterology 2010;31(3):190 194 Surgical Gastroenterology Evaluating the efficacy of tumor markers and CEA to predict operability and survival in pancreatic malignancies Jay Mehta, Ramkrishna
More informationTIMOTHY M. PAWLIK, RICHARD D. SCHULICK, MICHAEL A. CHOTI
The Oncologist Hepatobiliary Expanding Criteria for Resectability of Colorectal Liver Metastases TIMOTHY M. PAWLIK,RICHARD D. SCHULICK,MICHAEL A. CHOTI Department of Surgery, Johns Hopkins University School
More informationSentinel node biopsy in breast cancer patients treated with neoadjuvant chemotherapy
ONCOLOGY REPORTS 15: 927-931, 2005 927 Sentinel node biopsy in breast cancer patients treated with neoadjuvant chemotherapy YOSUKE TANAKA 1, HIRONORI MAEDA 2, YASUHIRO OGAWA 3, AKIHITO NISHIOKA 3, SATOSHI
More informationGallbladder Cancer. GI Practice Guideline. Michael Sanatani, MD, FRCPC (Medical Oncologist) Barbara Fisher, MD, FRCPC (Radiation Oncologist)
Gallbladder Cancer GI Practice Guideline Michael Sanatani, MD, FRCPC (Medical Oncologist) Barbara Fisher, MD, FRCPC (Radiation Oncologist) Approval Date: September 2006 This guideline is a statement of
More informationState of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan
State of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan Consultant GI Medical Oncologist National Cancer Centre Singapore Clinician Scientist, Genome Institute of Singapore OS (%) Overall survival
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Abdominoperineal excision, of rectal cancer, 93 111 current controversies in, 106 109 extent of perineal dissection and removal of pelvic floor,
More informationPrimary tumor with synchronous metastases
Metastatic colorectal cancer: special clinical situations Primary tumor with synchronous metastases Stefan Heinrich & Hauke Lang Department of General, Visceral and Transplantation Surgery University Hospital
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abdominal drainage, after hepatic resection, 159 160 Ablation, radiofrequency, for hepatocellular carcinoma, 160 161 Adenocarcinoma, pancreatic.
More informationEmbolotherapy for Cholangiocarcinoma: 2016 Update
Embolotherapy for Cholangiocarcinoma: 2016 Update Igor Lobko,MD Chief, Division Vascular and Interventional Radiology Long Island Jewish Medical Center GEST 2016 Igor Lobko, M.D. No relevant financial
More informationJose Ramos. Role of Surgery in isolated hepatic metastasis from breast carcinoma, melanoma or sarcoma
Role of Surgery in isolated hepatic metastasis from breast carcinoma, melanoma or sarcoma Jose Ramos University of the Witwatersrand Donald Gordon Medical Centre Evolution of liver resection Better understanding
More informationTHORACIC MALIGNANCIES
THORACIC MALIGNANCIES Summary for Malignant Malignancies. Lung Ca 1 Lung Cancer Non-Small Cell Lung Cancer Diagnostic Evaluation for Non-Small Lung Cancer 1. History and Physical examination. 2. CBCDE,
More informationKaoru Takeshima, Kazuo Yamafuji, Atsunori Asami, Hideo Baba, Nobuhiko Okamoto, Hidena Takahashi, Chisato Takagi, and Kiyoshi Kubochi
Case Reports in Surgery Volume 2016, Article ID 4548798, 5 pages http://dx.doi.org/10.1155/2016/4548798 Case Report Successful Resection of Isolated Para-Aortic Lymph Node Recurrence from Advanced Sigmoid
More informationSurgical Management of Pancreatic Cancer
I Congresso de Oncologia D Or July 5-6, 2013 Surgical Management of Pancreatic Cancer Michael A. Choti, MD, MBA, FACS Department of Surgery Johns Hopkins University School of Medicine, Baltimore, MD Estimated
More informationPosition Statement on Management of the Axilla in Patients with Invasive Breast Cancer
- Official Statement - Position Statement on Management of the Axilla in Patients with Invasive Breast Cancer Sentinel lymph node (SLN) biopsy has replaced axillary lymph node dissection (ALND) for the
More informationMetastatic Liver Cancer
4 Metastatic Liver Cancer ANDREW J. SMITH, MD, FRCSC RONALD P. DEMATTEO, MD YUMAN FONG, MD, FACS LESLIE H. BLUMGART, MD, FACS, FRCS (ENG, EDIN, GLAS) The management of hepatic metastases has become more
More informationTREATMENT OF PERITONEAL COLORECTAL CARCINOMATOSIS
TREATMENT OF PERITONEAL COLORECTAL CARCINOMATOSIS Anna Lepistö, MD, PhD Department of Colorectal Surgery, Abdominal Center, Helsinki University Hospital Incidence, prevalence and risk factors for peritoneal
More informationMetastatic mechanism of spermatic cord tumor from stomach cancer
Int Canc Conf J (2013) 2:191 195 DOI 10.1007/s13691-013-0-9 CANCER BOARD CONFERENCE Metastatic mechanism of spermatic cord tumor from stomach cancer Masahiro Seike Yoshikazu Kanazawa Ryuji Ohashi Tadashi
More informationSimultaneous Colorectal and Hepatic Resections for Colorectal Cancer: Postoperative and Longterm Outcomes
Simultaneous Colorectal and Hepatic Resections for Colorectal Cancer: Postoperative and Longterm Outcomes Eduardo de Santibañes, MD, FACS, Fernando Bonadeo Lassalle, MD, Lucas McCormack, MD, Juan Pekolj,
More informationAdvances in gastric cancer: How to approach localised disease?
Advances in gastric cancer: How to approach localised disease? Andrés Cervantes Professor of Medicine Classical approach to localised gastric cancer Surgical resection Pathology assessment and estimation
More informationGoéré et al. BMC Cancer (2018) 18:787
Goéré et al. BMC Cancer (2018) 18:787 https://doi.org/10.1186/s12885-018-4697-7 STUDY PROTOCOL Open Access Postoperative hepatic arterial chemotherapy in high-risk patients as adjuvant treatment after
More informationCOLORECTAL CARCINOMA
QUICK REFERENCE FOR HEALTHCARE PROVIDERS MANAGEMENT OF COLORECTAL CARCINOMA Ministry of Health Malaysia Malaysian Society of Colorectal Surgeons Malaysian Society of Gastroenterology & Hepatology Malaysian
More informationOncologic outcomes following metastasectomy in colorectal cancer patients developing distant metastases after initial treatment
ORIGINAL ARTICLE pissn 2288-6575 eissn 2288-6796 http://dx.doi.org/10.4174/astr.2015.88.5.253 Annals of Surgical Treatment and Research Oncologic outcomes following metastasectomy in colorectal cancer
More informationResection of liver limited resectable metastases Upfront, neoadjuvant and repeat hepatectomy
Resection of liver limited resectable metastases Upfront, neoadjuvant and repeat hepatectomy Dr Chan Chung Yip MBBS, M.Med(Surgery), MD, FAMS, FRCSEd Senior Consultant and Head Department of Hepatopancreatobiliary
More informationA Proposed Strategy for Treatment of Superficial Carcinoma. in the Thoracic Esophagus Based on an Analysis. of Lymph Node Metastasis
Kitakanto Med J 2002 ; 52 : 189-193 189 A Proposed Strategy for Treatment of Superficial Carcinoma in the Thoracic Esophagus Based on an Analysis of Lymph Node Metastasis Susumu Kawate,' Susumu Ohwada,'
More informationReference No: Author(s) Approval date: 12/05/16. Committee. June Operational Date: Review:
Reference No: Title: Author(s) Systemic Anti-Cancer Therapy (SACT) Guidelines for Biliary Tract Cancer (BTC) Dr Colin Purcell, Consultant Medical Oncologist on behalf of the GI Oncologists Group, Cancer
More informationChemotherapy of colon cancers
Chemotherapy of colon cancers Stage distribution Stage I : 15% T 1,2 NO Stage IV: 20 25% M+ Stage II : 20 30% T3,4 NO Stage III N+: 30 40% clinical stages I, II, or III colon cancer are at risk for having
More informationHepatic Resection of Noncolorectal Nonneuroendocrine Metastases
Hepatic Resection of Noncolorectal Nonneuroendocrine Metastases Alan W. Hemming, * Tim D. Sielaff, Steven Gallinger, * Mark S. Cattral, * Bryce R. Taylor, * Paul D. Greig, * and Bernard Langer * Because
More informationEvaluation of prognostic scoring systems for bone metastases using single center data
MOLECULAR AND CLINICAL ONCOLOGY 3: 1361-1370, 2015 Evaluation of prognostic scoring systems for bone metastases using single center data HIROFUMI SHIMADA 1, TAKAO SETOGUCHI 2, SHUNSUKE NAKAMURA 1, MASAHIRO
More informationClinical features and prognosis in hepatectomy for colorectal cancer with centrally located liver metastasis
Kuo et al. World Journal of Surgical Oncology (2015) 13:92 DOI 10.1186/s12957-015-0497-6 WORLD JOURNAL OF SURGICAL ONCOLOGY RESEARCH Open Access Clinical features and prognosis in hepatectomy for colorectal
More informationThe Glasgow prognostic score is valuable for colorectal cancer with both synchronous and metachronous unresectable liver metastases
324 The Glasgow prognostic score is valuable for colorectal cancer with both synchronous and metachronous unresectable liver metastases KENEI FURUKAWA, HIROAKI SHIBA, KOICHIRO HARUKI, YUKI FUJIWARA, TOMONORI
More informationState of the art management of Colorectal Liver Metastasis: an interplay of Chemotherapy and Surgical options
State of the art management of Colorectal Liver Metastasis: an interplay of Chemotherapy and Surgical options Ioannis S. Hatzaras, MD, MPH, FACS Assistant Professor of Surgery Division of Surgical Oncology
More informationPharmacologyonline 1: (2010)
THE EFFECT OF USING COMBINATION CHEMOTHERAPY IN COLORECTAL CANCER IN INDIA: A SINGLE INSTITUTE SURVEY Adiga Sachidananda*, Meena Kumari K**, Bairy KL***, Mohan Babu A**, Vadiraja BM+, Vidyasagar MS++ *Associate
More informationRandomized phase III trial of treatment duration for oral uracil and tegafur plus
Annals of Oncology Advance Access published September 7, 2015 1 Randomized phase III trial of treatment duration for oral uracil and tegafur plus leucovorin as adjuvant chemotherapy for patients with stage
More informationPhysician Follow-Up and Guideline Adherence in Post- Treatment Surveillance of Colorectal Cancer
Physician Follow-Up and Guideline Adherence in Post- Treatment Surveillance of Colorectal Cancer Gabriela M. Vargas, MD Kristin M. Sheffield, PhD, Abhishek Parmar, MD, Yimei Han, MS, Kimberly M. Brown,
More informationThe impact of operation center and the prognostic factors on the outcome of patients with stage II and stage III colorectal cancer
Turkish Journal of Cancer Volume 38, No. 4, 28 175 The impact of operation center and the prognostic factors on the outcome of patients with stage II and stage III colorectal cancer ABDULLAH BÜYÜKÇELİK
More informationE importante t che il chirurgo conosca il profilo molecolare del carcinoma del colon?
E importante t che il chirurgo conosca il profilo molecolare del carcinoma del colon? Giuseppe Aprile Dipartimento di Oncologia Dipartimento di Oncologia Azienda Ospedaliero-Universitaria - Udine Dr. Giuseppe
More informationTreatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy
Korean J Hepatobiliary Pancreat Surg 2011;15:152-156 Original Article Treatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy Suzy Kim 1,#, Kyubo
More informationInterval between Surgery and Radiation Therapy Is an Important Prognostic Factor in Treatment of Rectal Cancer
pissn 1598-2998, eissn 2005-9256 Cancer Res Treat. 2012;44(3):187-194 Original Article http://dx.doi.org/10.4143/crt.2012.44.3.187 Open Access Interval between Surgery and Radiation Therapy Is an Important
More informationRectal Cancer. GI Practice Guideline
Rectal Cancer GI Practice Guideline Dr. Brian Dingle MSc, MD, FRCPC Dr. Francisco Perera MD, FRCPC (Radiation Oncologist) Dr. Jay Engel MD, FRCPC (Surgical Oncologist) Approval Date: 2006 This guideline
More information